Valeant Tumbles After Q3 Miss, Downward Revised Guidance

  • Valeant Pharmaceuticals Intl Inc VRX reported Q3 earnings per share of $1.55, which was $0.20 per share less than expected.
  • Revenue of $2.48 billion fell a bit short of expectations.
  • Revenue fell 11 percent year-over-year due to a decline in sales from existing businesses, unfavorable foreign exchange and divestitures/discontinuations
  • Revenue did however grow on a sequential basis from $2.42 billion last quarter.
  • Net loss for the quarter totaled $1.22 billion compared to a net income of $49.5 million a year ago.
  • Valeant lowered its full year fiscal 2016 revenue guidance to range of $9.55 billion to $9.9 billion from a previous $10.1 billion.
  • Company also lowered full year earnings per share guidance to a range of $5.30 to $5.50 from a previous range of $6.60 to $7.00
  • Shares of Valeant lost around 8 percent to $17.51 early Tuesday morning.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsGuidanceValeant Pharmaceuticals Earnings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!